With a portfolio of 14 potential blockbuster treatments that it expects to launch over the next five years, GSK is sticking ...

GSK's Q2 earnings and revenues top forecasts, with Specialty Medicines and Vaccines driving growth and a raised 2025 outlook boosting shares.

As July concludes, the landscape of hematologic oncology continues to evolve, with notable progress in multiple myeloma, ...

Ionis Pharmaceuticals IONS reported second-quarter 2025 adjusted earnings per share (EPS) of 86 cents, significantly beating the Zacks Consensus Estimate of 27 cents. In the year-ago period, the ...

Encouraging early results from a SAHMRI-led clinical trial offer new hope to people diagnosed with chronic myelomonocytic ...

The biopharmaceutical industry is growing rapidly as a result of significant advancements in biotechnology and drug development. Due to developments in ...